Cervical cancer in Africa

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 9, 2012, Pages 1434-1438

  Denny, Lynette ^a   Anorlu, Rose ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SCREENING; CAUSE OF DEATH; COLORECTAL CANCER; COLPOSCOPY; DEATH; DRUG EFFICACY; EARLY DIAGNOSIS; EARLY INTERVENTION; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LUNG CANCER; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT MONITORING; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY CONTROL; SECONDARY PREVENTION; TREATMENT INDICATION; UTERINE CERVIX CANCER;

AFRICA; FEMALE; HUMANS; INCIDENCE; THERAPEUTICS; UTERINE CERVICAL NEOPLASMS;

EID: 84866145905     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0334     Document Type: Article

References (36)

1. Available from: http://globocan.iarc.fr/ and http://www.who.int/ hpvcentre.
2. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86.
3. World Health Statistics 2010, WHO Library Cataloguing-in-Publications Data, printed in France.
4. Ibrahim A, Rasch V, Pukkala E, Aro AR. Predictors of cervical cancer being at an advanced stage of diagnosis in Sudan. Int J Women's Health 2011;3:385-9.
5. Gondos A, Brenner H, Wabinga H, Parkin DM. Cancer survival in Kampala, Uganda. Br J Cancer 2005;92:1808-12.
6. Gondos A, Chokunonga E, Brenner H, Parkin DM, Sankila R, Borok M. Cancer survival in a southern African urban population. Int J Cancer 2004;112:860-4.
7. Independent Evaluation Group Studies. Annual review of development effectiveness: achieving sustainable development. Geneva, Switzerland; World Bank; 2009.
8. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population based study. Lancet Oncol 2010;11:165-73.
9. WHO, Working Together for Health: the World Health Report 2006. Geneva: WHO; 2006).
10. Hanna T, Kangolle A. Cancer control in developing countries: using health data and health services research to measure and improve access. Quality and efficiency.BMCInt HealthHumRights 2010;10:24.
11. Scheffler RM, Mahoney CB, Fulton BD, Dal Poz MR, Preker AS. Estimates of health care professional shortages in sub-saharan Africa by 2015. Heath Aff 2009;28:849-62.
12. Available from: www.unaids.org/2010 report.
13. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
14. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008b;17:545-54.
15. Denny L, Boa R, Williamson AL, Allan B, Hardie D, Ress S, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women. Obstet Gynecol 2008;111:1380-87.
16. Barton MB, Frommer M, Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 2006;7:584-95.
17. Ashraf H. Poor nations need more help to slow growing cancer burden. Lancet 2003;361:2209.
18. Anorlu RI. Cervical cancer: the sub-Saharan African Perspective. Reprod Health Matters 2008;16:41.
19. Van Der Giessen PH, Alert J, Badri C, Bistrovic M, Deshpande D, Kardamakis D, et al. Multinational assessment of some operational costs of teletherapy. Radiother Oncol 2004;71:347-55.
20. Levin V, Tatsuzaki H. Radiotherapy services in countries in transition: gross national income per capita as a significant factor. Radiother Oncol 2002;63:147-50.
21. Logie DE, Harding R. An evaluation of a morphine public health programme for cancer and AIDS pain relief in Sub-Saharan Africa. BMC Public Health 2005;5:1-7.
22. Denny L, Quinn M, Sankaranarayanan R. Screening for cervical cancer in developing countries. Vaccine 2006;24S3:S3/71-77.
23. Sauveget C, Fayette JM, Muwonge R, Wesley R, Sanakaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011;113:14-24.
24. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010;102:1-11.
25. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh A, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
26. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV DNA test for cervical cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36.
27. Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010;48:4646-8.
28. Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen H, Skomedal H, et al. Value of high-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect™ HPV-Proofer to detect cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol. 2012.
29. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-65.
30. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanaowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-55.
31. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;372:1645-51.
32. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
33. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 & 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
34. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
35. Roteli-Martins C, Naud P, De Borba P, Teixeira J, De Carvalho N, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccine Immunother 2012;1:8.
36. Available from: www.gavialliance.org.